Patents by Inventor Paul A. Knepper
Paul A. Knepper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230270689Abstract: Neurodegenerative diseases are treated by the co-administration to a subject of an effective amount of a stilbene, a flavonol, and a TLR4/MD2 receptor antagonist. A preferred stilbene is resveratrol, a preferred flavonol is quercetin, and a preferred TLR4/MD2 receptor antagonist is curcumin.Type: ApplicationFiled: May 3, 2023Publication date: August 31, 2023Inventor: Paul A. Knepper
-
Patent number: 11723343Abstract: A system for determining the gender and/or fertility status of avian eggs including a sampling apparatus and an electromagnetic radiation transmitter and detector. In certain embodiments, the transmitter operates in the terahertz range. The sampling apparatus can be coupled to an avian egg. The sampling apparatus includes a vacuum source, a gas collection device, and a membrane that can be positioned in the passageway coupling the vacuum source to the gas collection device. The membrane is capable of capturing volatile organic compounds. The sampling apparatus applies a vacuum from the vacuum source to the gas proximate to the avian egg and directs the gas captured from the vicinity of the egg toward the membrane. Subsequently, the membrane is positioned within the electromagnetic radiation emitted by the transmitter, generating a spectrum which can be analyzed to determine whether the egg is fertile or infertile, and if fertile, whether the egg is male or female.Type: GrantFiled: March 30, 2021Date of Patent: August 15, 2023Assignee: NOVATRANS GROUP S.A.Inventors: Paul Knepper, Matthew O'Hayer, Jonathan Hoopes, Eran Gabbai
-
Patent number: 11570971Abstract: A system for determining the gender and/or fertility status of avian eggs including a sampling apparatus and an electromagnetic radiation transmitter and detector. In certain embodiments, the transmitter operates in the terahertz range. The sampling apparatus can be coupled to an avian egg. The sampling apparatus includes a vacuum source, a gas collection device, and a membrane that can be positioned in the passageway coupling the vacuum source to the gas collection device. The membrane is capable of capturing volatile organic compounds. The sampling apparatus applies a vacuum from the vacuum source to the gas proximate to the avian egg and directs the gas captured from the vicinity of the egg toward the membrane. Subsequently, the membrane is positioned within the electromagnetic radiation emitted by the transmitter, generating a spectrum which can be analyzed to determine whether the egg is fertile or infertile, and if fertile, whether the egg is male or female.Type: GrantFiled: March 30, 2021Date of Patent: February 7, 2023Assignee: Novatrans Group S.A.Inventors: Paul Knepper, Matthew O'Hayer, Jonathan Hoopes, Eran Gabbai
-
Publication number: 20220175697Abstract: Age-related macular degeneration (AMD) is treated by administration of a stilbene, a flavonol, and curcumin or a biologically active curcumin analog to a patient afflicted with AMD.Type: ApplicationFiled: January 13, 2022Publication date: June 9, 2022Inventor: Paul A. Knepper
-
Patent number: 11234942Abstract: Pharmaceutical compositions containing a stilbene such as resveratrol, a flavonol such as quercetin, and a TLR4/MD2 receptor antagonist such as naltrexone or curcumin inhibit aggregation of superactivated platelets, block activation of the coagulation cascade, and are useful for treating microvascular diseases including neurodegenerative diseases such as Alzheimer's disease and dementia, for treating primary open-angle glaucoma, for reducing scar formation, and like afflictions that involve the coagulation cascade.Type: GrantFiled: February 14, 2019Date of Patent: February 1, 2022Inventor: Paul A. Knepper
-
Publication number: 20210212297Abstract: A system for determining the gender and/or fertility status of avian eggs including a sampling apparatus and an electromagnetic radiation transmitter and detector. In certain embodiments, the transmitter operates in the terahertz range. The sampling apparatus can be coupled to an avian egg. The sampling apparatus includes a vacuum source, a gas collection device, and a membrane that can be positioned in the passageway coupling the vacuum source to the gas collection device. The membrane is capable of capturing volatile organic compounds. The sampling apparatus applies a vacuum from the vacuum source to the gas proximate to the avian egg and directs the gas captured from the vicinity of the egg toward the membrane. Subsequently, the membrane is positioned within the electromagnetic radiation emitted by the transmitter, generating a spectrum which can be analyzed to determine whether the egg is fertile or infertile, and if fertile, whether the egg is male or female.Type: ApplicationFiled: March 30, 2021Publication date: July 15, 2021Applicant: NOVATRANS GROUP S.A.Inventors: Paul Knepper, Matthew O'Hayer, Jonathan Hoopes, Eran Gabbai
-
Publication number: 20210212296Abstract: A system for determining the gender and/or fertility status of avian eggs including a sampling apparatus and an electromagnetic radiation transmitter and detector. In certain embodiments, the transmitter operates in the terahertz range. The sampling apparatus can be coupled to an avian egg. The sampling apparatus includes a vacuum source, a gas collection device, and a membrane that can be positioned in the passageway coupling the vacuum source to the gas collection device. The membrane is capable of capturing volatile organic compounds. The sampling apparatus applies a vacuum from the vacuum source to the gas proximate to the avian egg and directs the gas captured from the vicinity of the egg toward the membrane. Subsequently, the membrane is positioned within the electromagnetic radiation emitted by the transmitter, generating a spectrum which can be analyzed to determine whether the egg is fertile or infertile, and if fertile, whether the egg is male or female.Type: ApplicationFiled: March 30, 2021Publication date: July 15, 2021Applicant: NOVATRANS GROUP S.A.Inventors: Paul Knepper, Matthew O'Hayer, Jonathan Hoopes, Eran Gabbai
-
Patent number: 11006617Abstract: A system for determining the gender and/or fertility status of avian eggs including a sampling apparatus and an electromagnetic radiation transmitter and detector. In certain embodiments, the transmitter operates in the terahertz range. The sampling apparatus can be coupled to an avian egg. The sampling apparatus includes a vacuum source, a gas collection device, and a membrane that can be positioned in the passageway coupling the vacuum source to the gas collection device. The membrane is capable of capturing volatile organic compounds. The sampling apparatus applies a vacuum from the vacuum source to the gas proximate to the avian egg and directs the gas captured from the vicinity of the egg toward the membrane. Subsequently, the membrane is positioned within the electromagnetic radiation emitted by the transmitter, generating a spectrum which can be analyzed to determine whether the egg is fertile or infertile, and if fertile, whether the egg is male or female.Type: GrantFiled: July 31, 2017Date of Patent: May 18, 2021Assignee: NOVATRANS GROUP S.A.Inventors: Paul Knepper, Matthew O'Hayer, Jonathan Hoopes, Eran Gabbai
-
Publication number: 20210106542Abstract: Inhibition of aggregation of superactivated platelets, blocking of activation of coagulation cascade, treatment of primary open-angle glaucoma, and treatment of microvascular diseases is effected by co-administration of a stilbene, a flavonol, and a ?-opioid receptor antagonist.Type: ApplicationFiled: December 22, 2020Publication date: April 15, 2021Inventor: Paul A. Knepper
-
Publication number: 20190174726Abstract: A system for determining the gender and/or fertility status of avian eggs including a sampling apparatus and an electromagnetic radiation transmitter and detector. In certain embodiments, the transmitter operates in the terahertz range. The sampling apparatus can be coupled to an avian egg. The sampling apparatus includes a vacuum source, a gas collection device, and a membrane that can be positioned in the passageway coupling the vacuum source to the gas collection device. The membrane is capable of capturing volatile organic compounds. The sampling apparatus applies a vacuum from the vacuum source to the gas proximate to the avian egg and directs the gas captured from the vicinity of the egg toward the membrane. Subsequently, the membrane is positioned within the electromagnetic radiation emitted by the transmitter, generating a spectrum which can be analyzed to determine whether the egg is fertile or infertile, and if fertile, whether the egg is male or female.Type: ApplicationFiled: July 31, 2017Publication date: June 13, 2019Inventors: Paul Knepper, Matthew O'Hayer, Jonathan Hoopes, Eran Gabbai
-
Publication number: 20190175522Abstract: Pharmaceutical compositions containing a stilbene such as resveratrol, a flavonol such as quercetin, and a TLR4/MD2 receptor antagonist such as naltrexone or curcumin inhibit aggregation of superactivated platelets, block activation of the coagulation cascade, and are useful for treating microvascular diseases including neurodegenerative diseases such as Alzheimer's disease and dementia, for treating primary open-angle glaucoma, for reducing scar formation, and like afflictions that involve the coagulation cascade.Type: ApplicationFiled: February 14, 2019Publication date: June 13, 2019Inventor: Paul A. Knepper
-
Publication number: 20190046466Abstract: Pharmaceutical compositions containing a stilbene such as resveratrol, a flavonol such as quercetin, and a ?-opioid receptor antagonist such as naltrexone inhibit aggregation of superactivated platelets, block activation of the coagulation cascade, and are useful for treating microvascular diseases including neurodegenerative diseases such as Alzheimer's disease and dementia, for treating primary open-angle glaucoma, for reducing scar formation, and like afflictions that involve the coagulation cascade.Type: ApplicationFiled: August 18, 2016Publication date: February 14, 2019Inventor: Paul A. Knepper
-
Patent number: 7375957Abstract: A system for facilitating transport of a computer and monitor as a unit is disclosed, and comprises a computer case having an exterior, a support located on the computer case for supporting the monitor on the computer case, and a binder for removably binding the monitor to the computer case when the monitor is positioned on the support. The system may also include a handle located on the exterior of the computer case for being gripped by a hand of a user.Type: GrantFiled: September 29, 2006Date of Patent: May 20, 2008Assignee: Gateway Inc.Inventor: Paul A. Knepper
-
Publication number: 20080080127Abstract: A system for facilitating transport of a computer and monitor as a unit is disclosed, and comprises a computer case having an exterior, a support located on the computer case for supporting the monitor on the computer case, and a binder for removably binding the monitor to the computer case when the monitor is positioned on the support. The system may also include a handle located on the exterior of the computer case for being gripped by a hand of a user.Type: ApplicationFiled: September 29, 2006Publication date: April 3, 2008Inventor: Paul A. Knepper
-
Patent number: 4812448Abstract: A novel pharmacologic therapy for treatment of idiopathic primary open angle glaucoma, drug-induced glaucoma and elevated intraocular pressure is disclosed. The pharmacologic therapy consists of a novel composition comprised of 17-alpha-methyl-testosterone and a physiologically tolerable carrier. In accordance with a method aspect of this invention, the active ingredient is administered to the eye of a warm blooded animal in such a manner as to maintain physiologic or normal intraocular pressure, or to return elevated intraocular pressure to normal levels. The method aspect of this invention may also be employed to ameliorate drug induced elevated intraocular pressure.Type: GrantFiled: October 14, 1986Date of Patent: March 14, 1989Inventor: Paul A. Knepper
-
Patent number: 4617299Abstract: A novel pharmacologic therapy for treatment of idiopathic primary open angle glaucoma, drug-induced glaucoma and elevated intraocular pressure is disclosed. The pharmacologic therapy consists of a novel composition comprised of a selected anabolic androgenic compound and a physiologically tolerable carrier. In accordance with a method aspect of this invention, the pharmacologic substance is administered to the eye of a warm blooded animal in such a manner as to maintain physiologic or normal intraocular pressure, or to return elevated intraocular pressure to normal levels. The method aspect of this invention may also be employed to prevent drug induced elevated intraocular pressure.Type: GrantFiled: October 22, 1984Date of Patent: October 14, 1986Inventor: Paul A. Knepper